Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions
Alagille Syndrome
Interventions
DRUG

Odevixibat

Odevixibat is a small molecule and selective inhibitor of IBAT.

DRUG

Placebo

Placebo identical in appearance to experimental drug (odevixibat).

Trial Locations (32)

1023

Starship Child Health, Auckland

1200

Cliniques Universitaires Saint-Luc Bruxelles, Brussels

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center, New York

10467

The Childrens Hospital at Montefiore Albert Einstein School of Medicine, The Bronx

13353

Charité-Universitätsmedizin Berlin, Berlin

13385

APHM, Marseille

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

21287

Johns Hopkins Hospital, Baltimore

24127

ASST Papa Giovanni XXIII, Bergamo

30625

Medizinische Hochschule Hannover, Hanover

34093

Istanbul University Medical Faculty Hospital, Fatih

35128

Azienda Ospedale Università Padova, Padua

50139

AOU Meyer, Florence

59037

Antenne pédiatrique du CIC - Hopital Jeanne De Flandre, Lille

59100

University of Malaya Medical Centre, Kuala Lumpur

64108

Children's Mercy Hospital and Clinics, Kansas City

69677

Hôpital Femme Mère Enfant de Lyon, Bron

72076

Universitätsklinik für Kinder-und Jugendmedizin Tübingen, Tübingen

75015

Hopital Necker Enfants Malades, Paris

94158

University of California - San Francisco, San Francisco

97239

Oregon Health Science University School of Medicine, Portland

4920235

Schneider Children's Medical Center of Israel, Petah Tikva

9103102

Sharie Zedek, Jerusalem

02115

Boston Children's Hospital, Boston

H3T 1C5

CHU Sainte-Justine, Montreal

00165

Bambino Gesù Children's Hospital, Rome

9713 GZ

Universitair Medisch Centrum Groningen (UMCG), Groningen

3584EA

University Medical Centre Utrecht, WKZ, Utrecht

04-730

Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw

06230

Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi, Ankara

SE5 9RS

King's College Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Albireo

INDUSTRY

NCT04674761 - Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome | Biotech Hunter | Biotech Hunter